Navi Mumbai Airport cleared for drug imports, entry points rise to 42
Synopsis
India has quietly expanded its pharmaceutical import infrastructure by adding the newly opened Navi Mumbai Airport to its list of approved drug-entry points, bringing the total to 42. A simultaneous move scraps licensing for small R&D drug imports — a change that could meaningfully lower barriers for start-ups and research labs racing to initiate testing.
Key Takeaways
The Ministry of Health and Family Welfare has added Navi Mumbai Airport to the list of approved drug-import entry points via an amendment to Rule 43A of the Drugs Rules, 1945 .
India's total designated pharmaceutical import ports now stand at 42 .
The notification was issued after consultation with the Drugs Technical Advisory Board under the Drugs and Cosmetics Act, 1940 .
A separate June 2025 amendment introduces an acknowledgement-based system for importing small drug quantities for testing or R&D, eliminating licensing requirements.
The reforms aim to ease logistics for commercial importers and reduce compliance burden for start-ups and research organisations.
The Ministry of Health and Family Welfare has authorised the import of pharmaceutical products through the newly inaugurated Navi Mumbai Airport in Maharashtra, raising the total number of designated drug-import entry points across India to 42 ports, according to an official statement issued on Wednesday, 8 July 2025. The move amends Rule 43A of the Drugs Rules, 1945 and is expected to ease logistics pressure on existing pharmaceutical import corridors.
What the Amendment Does
The notification, issued after consultation with the Drugs Technical Advisory Board under the Drugs and Cosmetics Act, 1940, formally adds Navi Mumbai Airport to the list of approved entry points for drug consignments. The ministry described the change as a step toward 'smoother movement of pharmaceutical consignments, strengthened logistics infrastructure, and greater flexibility for importers.'
By diversifying the number of approved ports, the government aims to reduce congestion at existing hubs and give pharmaceutical companies more routing options for time-sensitive medicines and active pharmaceutical ingredients.
Parallel Reform: Easing R&D Imports via Form 11
Separately, the ministry had in June 2025 proposed amendments to simplify the procedure for importing drugs for examination, testing, or analysis — a process governed by what is commonly known as Form 11. The revised framework introduces an acknowledgement-based system for importing small quantities of drugs intended for analytical and non-clinical testing purposes.
Crucially, the amendment eliminates licensing requirements for such imports, significantly reducing the compliance burden on applicants — particularly start-ups and research institutions that need to quickly initiate testing or analysis without navigating a lengthy approval process.
Impact on the Pharmaceutical Sector
The dual set of reforms targets two distinct pain points: logistics bottlenecks for commercial drug imports, and regulatory friction for research-stage imports. Together, they signal a deliberate effort by the Centre to position India as a more competitive destination for pharmaceutical investment and innovation.
Industry observers note that the acknowledgement-based import route for R&D quantities could be especially consequential for early-stage biotech firms and contract research organisations, which have historically cited Form 11 delays as a barrier to timely project initiation. This is in line with the government's broader ease of doing business agenda within the healthcare and life sciences sector.
Regulatory Oversight Remains in Place
The ministry was explicit that the liberalisation does not dilute regulatory scrutiny. Officials stated that the changes are designed to 'ensure effective regulatory oversight of imported drugs' even as procedural steps are streamlined. The Drugs Technical Advisory Board's involvement in the notification process underscores that technical and safety standards remain non-negotiable.
With Navi Mumbai Airport now operational and integrated into the pharmaceutical import framework, stakeholders will be watching whether the new entry point meaningfully reduces turnaround times for consignments routed through Mumbai — India's largest pharmaceutical trade hub. Further amendments to the Drugs Rules are expected as the government continues its regulatory modernisation drive.
Point of View
But the more consequential reform is the acknowledgement-based route for R&D drug imports. Licensing delays under the old Form 11 regime have been a persistent, underreported friction point for India's biotech and contract research ecosystem. If the new system is implemented without fresh bureaucratic workarounds, it could materially accelerate early-stage drug development timelines. The real test, however, is implementation: India has a pattern of announcing procedural simplifications that get quietly complicated at the port or zonal drug authority level. Whether these amendments translate into faster clearances on the ground — rather than just cleaner rules on paper — will determine their actual impact on pharmaceutical sector competitiveness.
NationPress
8 Jul 2026
Frequently Asked Questions
Why has Navi Mumbai Airport been added to the drug import list?
The Ministry of Health and Family Welfare amended Rule 43A of the Drugs Rules, 1945 to include Navi Mumbai Airport as an approved entry point for pharmaceutical consignments, bringing the total number of designated import ports to 42. The move is intended to ease logistics, reduce congestion at existing hubs, and give importers greater routing flexibility.
What is the acknowledgement-based system for drug imports?
It is a simplified procedure introduced for importing small quantities of drugs for testing, examination, or analysis — previously governed by Form 11. Under the new system, applicants no longer need a licence for such imports; an acknowledgement suffices, significantly cutting compliance time for start-ups and research institutions.
Which regulatory body was consulted before issuing the notification?
The notification was issued after consultation with the Drugs Technical Advisory Board, the apex technical body under the Drugs and Cosmetics Act, 1940. This ensures that the liberalisation does not compromise drug safety or quality standards.
Who benefits most from these amendments?
Commercial pharmaceutical importers benefit from the additional entry point at Navi Mumbai Airport, while start-ups, biotech firms, and contract research organisations stand to gain the most from the scrapping of licensing requirements for small R&D drug imports, which had previously slowed testing and analysis timelines.
Does easing import rules mean reduced safety oversight?
No. The ministry has stated that the amendments are designed to maintain effective regulatory oversight of imported drugs. Procedural steps have been streamlined, but technical and safety standards under the Drugs and Cosmetics Act, 1940 remain in force.
